| 引用本文:关念波1，2 王 辉1，2 林洪生1，2.晚期非小细胞肺癌化疗后中医药巩固治疗疗效分析[J].世界中医药,2014,9(04):. |
|
| 晚期非小细胞肺癌化疗后中医药巩固治疗疗效分析 |
| A Clinical Retrospective Study of Patients with Late Stage Non-small Cell Lung Cancer Treating by Traditional Chinese Medicine after Two Cycles of Chemotherapy |
| 投稿时间：2014-03-16 |
| DOI：10.3969/j.issn.1673-7202.2014.04.016 |
| 中文关键词: 非小细胞肺癌 化疗 中药 疗效 |
| English Keywords:Non-small-cell lung cancer Chemotherapy Chinese medicine Efficacy |
| 基金项目:国家十一五科技支撑计划项目（编号：2006BAI04A05） |
|
| 摘要点击次数: 1200 |
| 全文下载次数: 1451 |
| 中文摘要: |
| 目的：探讨晚期非小细胞肺癌（Non-Small-Cell Lung Cancer，NSCLC）化疗后中医药巩固治疗的疗效。方法：回顾性分析晚期NSCLC患者临床资料。观察治疗后疗效评价、疾病进展时间（Time to Progression,TTP）、1年生存率、总生存（Overall Survival,OS）。结果：持续化疗4周期有效率（CR+PR+SD）84.9%；化疗2周期后加中医巩固治疗2周期有效率（CR+PR+SD）82.7%，差异无统计学意义（P=0.554）。剔除2周期化疗后肿瘤进展（PD）患者，持续化疗组中位TTP 5.0个月，中医巩固治疗组中位TTP 4.0个月，差异无统计学意义（P=0.183）。持续化疗组1年生存率57.5%，中医巩固治疗组为60.0%，差异无统计学意义（0.952）。化疗组中位OS 17个月，中医巩固治疗组16个月，差异无统计学意义（P=0.715）。结论：对于前期化疗疗效稳定的晚期NSCLC患者，中医药在维持瘤体大小、延缓病情进展方面具有一定作用，疗效不劣于继续化疗，值得进一步研究。 |
| English Summary: |
| To observe the efficacy of traditional Chinese medicine in treating the advanced non-small cell lung cancer (NSCLC) after chemotherapy. Methods： A clinical retrospective analysis of the patients with advanced NSCLC was done. Main out come meansures：： Efficacy evaluation, Time to disease progression (TTP), One year survival rate, Overall survival (OS). Results： After four cycles of treatment, there were 62 (84.9%) CR + PR + SD cases in the chemotherapy group while 62 cases (82.7%) in the Chinese medicine treatment group, but the difference was not statistically significant (P=0.554). The stratified statistics for the two groups excluding PD patients came out that the median TTP of chemotherapy group was 5.0 months and 4.0 months of the Chinese medicine group with no statistically significant difference (P= 0.183). One year survival rate of chemotherapy group was 57.5%, and it was 60.0% of Chinese medicine group, the difference was not statistically significant (0.952). The chemotherapy group’s median OS was 17 months, traditional Chinese medicine’s OS was 16 months, the difference was not statistically significant (P= 0.715). Conclusion： For the advanced NSCLC patients whose efficacy evaluation of pre-treatment was stable, the choice of Chinese medicine treatment would show a positive role in maintaining tumor size and decelerating the disease progression. And the effect is not inferior to continue chemotherapy. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
